Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Maintenance in CD30+ PTCL
NCT06550336Phase 2Active, not recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by The First Hospital of Jilin University. Started Jun 2024; status: active, not recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06550336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550336.